Some new investors pitched in to Recursion Pharmaceuticals Inc.'s $121 million series C financing, adding to the industry's vision of the importance of AI and machine learning.

Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform ...

Recursion announces the close of a $121 million Series C financing to advance its machine learning-enabled approach to drug discovery and development.

So where will Recursion be in five years, and is the stock worth buying today? There's a lot coming up Today, Recursion has no products approved for sale.